Molecular Allergy Diagnostics in Peanut Allergy

Peanut allergy represents one of the most common and potentially severe food allergies, affecting both paediatric and adult populations across Europe and the United Kingdom. Its clinical presentation is highly variable, ranging from mild localised symptoms to life-threatening anaphylaxis, creating significant anxiety and impairing quality of life for affected individuals and their families. The primary goal of modern allergological practice is not only to confirm sensitisation but to accurately stratify individual risk, thereby enabling personalised management plans that balance necessary vigilance with improved quality of life.

Traditional diagnostic modalities, namely the skin prick test (SPT) and the measurement of peanut-specific immunoglobulin E (sIgE) antibodies, have been the cornerstone of allergy investigation for decades. While these tests are highly sensitive for detecting sensitisation to the whole peanut extract, they possess a well-documented limitation: they are poor predictors of clinical reaction severity.

A markedly elevated sIgE level or a large SPT wheal may indicate a higher probability of a clinical reaction but does not reliably distinguish between patients who will experience mild oral allergy syndrome and those at genuine risk of anaphylaxis. This diagnostic ambiguity often leads to the implementation of overly restrictive precautionary measures or, conversely, to an underestimation of genuine risk.

The critical advancement in elucidating this heterogeneity lies in component-resolved diagnostics (CRD). Peanuts contain numerous allergenic proteins, each with distinct biochemical properties and clinical implications. The immune system of a sensitised individual can produce IgE antibodies against one or several of these specific protein components. The stability of these proteins to heat and enzymatic digestion is a key determinant of the severity of the allergic reaction they provoke. The major peanut allergens include Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara h 8, and Ara h 9.

The stable storage proteins, Ara h 1, Ara h 2, Ara h 3, and Ara h 6, are resistant to cooking and gastrointestinal digestion. Sensitisation to these components, particularly Ara h 2, which is recognised as the most potent predictor, is strongly associated with systemic and potentially severe reactions upon ingestion. The presence of significant levels of sIgE to Ara h 2 is a key biomarker for a high risk of anaphylaxis. Conversely, sensitisation primarily to Ara h 8, a pathogenesis-related (PR-10) protein homologue of the major birch pollen allergen Bet v 1, typically indicates a milder phenotype. Ara h 8 is labile, easily destroyed by heat and digestion, and often leads to symptoms confined to the oropharynx (pollen-food allergy syndrome), as the reactive IgE is cross-reactive due to prior birch pollen sensitisation.

The availability of multiplex testing platforms, such as the Allergy Explorer (ALEX) biochip array, has greatly facilitated comprehensive component-resolved diagnosis. This in vitro diagnostic tool allows for the simultaneous quantification of sIgE antibodies against a vast array of allergenic extracts and molecular components, including the full spectrum of relevant peanut proteins, from a single small blood sample. The resultant sensitisation profile provides the clinician with a molecular fingerprint of the patient’s allergy, moving the diagnosis from a probabilistic to a more personalised and predictive model.

This detailed immunological information is indispensable for clinical management. Identifying a profile dominated by anti-Ara h 2 IgE supports the necessity of strict peanut avoidance, the prescription of adrenaline auto-injectors, and the formulation of a robust anaphylaxis management plan. In contrast, a profile showing isolated sensitisation to Ara h 8, especially in the context of birch pollen allergy, may allow for a more nuanced approach, potentially including supervised oral challenges to confirm tolerance to baked peanut or to define the threshold for symptom elicitation, thereby liberating the patient from undue dietary and social restrictions.

Oral immunotherapy

Oral immunotherapy (OIT) for peanut allergy remains an area of intense research. While certain formulations have received regulatory approval in some regions, its application in routine clinical practice is still constrained by a significant incidence of treatment-emergent adverse events, including anaphylaxis, and the persistence of a state of transient desensitisation rather than durable remission. The decision to pursue OIT requires careful patient selection and specialist supervision in a highly controlled setting; it is not currently considered a standardised or risk-free treatment for the general peanut-allergic population.

In conclusion, the integration of molecular allergology into diagnostic algorithms represents a paradigm shift in the management of peanut allergy. By delineating the specific sensitisation profile, clinicians can prognosticate more accurately, tailor counselling, and empower patients with knowledge that is precisely relevant to their individual immunological risk. This precision medicine approach is fundamental to optimising both safety and quality of life.

References

1. Kansen HM, Le TM, Meijer Y, et al. The predictive value of component-specific IgE for the outcome of peanut introduction in peanut-allergic patients. Pediatr Allergy Immunol. 2021;32(1):166-173.
2. Santos AF, Douiri A, Bécares N, et al. Basophil activation test discriminates between allergy and tolerance in peanut-sensitized children. J Allergy Clin Immunol. 2014;134(3):645-652.
3. Beyer K, Grabenhenrich L, Härtl M, et al. Predictive values of component-specific IgE for the outcome of peanut and hazelnut food challenges in children. Allergy. 2015;70(1):90-98.
4. Nilsson C, Berthold M, Mascialino B, et al. Accuracy of component-resolved diagnostics in peanut allergy: systematic literature review and meta-analysis. Pediatr Allergy Immunol. 2020;31(3):303-314.
5. Vereda A, van Hage M, Ahlstedt S, et al. Peanut allergy: Clinical and immunologic differences among patients from 3 different geographic regions. J Allergy Clin Immunol. 2011;127(3):603-607.
6. Klemans RJ, van Os-Medendorp H, Blankestijn M, Bruijnzeel-Koomen CA, Knol EF, Knulst AC. Diagnostic accuracy of component-resolved diagnostics for peanut allergy: a systematic review. Allergy. 2015;70(4):433-443.
7. Blumchen K, Beder A, Beschorner J, et al. Modified oral food challenge used with sensitization biomarkers provides more real-life clinical thresholds for peanut allergy. J Allergy Clin Immunol. 2019;144(2):381-390.e3.
8. Tsilochristou OA, du Toit G, Sayre PH, et al. Association of specific, sensitization patterns to peanut allergen components with asthma and airway hyperresponsiveness in peanut‐allergic subjects. Clin Exp Allergy. 2020;50(6):717-724.